| DB ID | MyCo_1529 |
| Title | Clinical applications of interferon-γ releasing assays for cytomegalovirus to differentiate cytomegalovirus disease from bystander activation: a pilot proof-of-concept study |
| Year | 2016 |
| PMID | 28830137 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | cytomegalo virus (CMV) co-infection |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | The study protocol was approved by the Institutional Review Board of Asan Medical Center (no. 2014-0198). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | IFN-γ |
| Biomarker Full Name | Interferon gamma |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | South Korea |
| Cohort | We prospectively enrolled all non-human immunode¬ficiency virus (HIV) infected adult patients with con¬firmed PCP combined with suspected CMV pneumo¬nia, and those with suspected gastrointestinal CMV disease, who were admitted between January 2014 and December 2014 to the Asan Medical Center, a 2,700-bed tertiary hospital in Seoul, South Korea. Tests for CMV immunoglobulin G were performed in the hema¬topoietic stem cell transplant (HCT) recipients and sol¬id organ transplant recipients. All HCT or solid organ transplant recipients were monitored for CMV antigen¬emia during the post-transplant period. |
| Cohort No. | 41 PCP Patients + 35 CMV Patients |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Cytomegalovirus (CMV) is a major cause of morbidity and a preventable cause of mortality in immunocom promised patients. CMV is frequently reactivated in immunocompromised patients, so where there is evi¬dence of CMV replication it is difficult to differentiate CMV disease from bystander activation. The serolog¬ic test of CMV, the detection of CMV viremia (i.e., CMV deoxyribonucleic academia by polymerase chain reac¬tion [PCR], pp65 CMV antigenemia), and virus isolation by CMV culture or PCR from various specimen are the mainstay for the diagnosis of CMV infection. In addition, the direct examination of CMV-specific histopathologic findings with CMV immunohistochemistry or PCR in tissue biopsy is useful in the diagnosis of localized CMV tissue-invasive disease. |
| Technique | Assay |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA QuantiFERON-CMV (Cellestis, Valencia, CA, USA) and ELISA (ELISPOT) T-track-CMV (Lo¬phius Biosciences, Regensburg, Germany). |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
